Drug Payer & Channel Explorer
2023Search and select one or more drugs from the 532 unique medicines in the MEPS 2023 prescribed medicines file after excluding missing drug names (187,060 fills, 11,836 patients). Selected drugs are combined into one view — who paid, and where the prescription was filled.
Coverage, in AHRQ's own words: "Each record represents one household-reported fill or refill of a prescribed medicine that was obtained during calendar year 2023 at any retail pharmacy, including mail-order or on-line." And on what's out of scope: "The HC does not collect information on drugs administered in healthcare settings" — respondents report drugs prescribed during a doctor's-office, clinic, ER, or inpatient visit only if the drug was subsequently filled, not drugs given during the visit itself. That's why IV-infused oncology biologics (Herceptin/trastuzumab, Keytruda/pembrolizumab, Perjeta/pertuzumab, Avastin/bevacizumab, Opdivo/nivolumab — all 0 records here) and other in-office-administered products (Nexplanon, IUDs) don't appear: they're billed as part of the clinical visit, captured in MEPS's Office-Based or Outpatient event files instead. Sources: AHRQ MEPS HC-248A 2023 documentation §2.0; Methodology Report #37, "Household Component" §.
Names are generic / molecule names, not brand names — e.g. search atorvastatin for Lipitor, escitalopram for Lexapro, levothyroxine for Synthroid. Per AHRQ: "This drug name [RXDRGNAM] is the generic name of the drug most commonly used by prescribing physicians. It is supplied by the Multum Lexicon database." A generic name can cover multiple brand-name and store-brand products. A handful of entries in this list (e.g. "Hormones/Hormone Modifiers") are not real drug names at all — AHRQ masks orphan drugs and drugs estimated to be used by fewer than 400,000 people nationally, for confidentiality, and recodes them down to their therapeutic class instead.
TABS) come
verbatim from Appendix 1, "Definitions for RXFORM, Dosage Form," of AHRQ's own HC-248A documentation (558
codes). Some codes have no label because AHRQ's own table marks them "no definition for the dosage form" —
for example SOPN, SOAJ, and PSKT are undefined even in the official
source, not a gap in our mapping. The raw code is always shown alongside the label so you can verify it
against the source yourself.
Source: AHRQ MEPS HC-248A 2023 documentation, Appendix 1. Source. AHRQ, 2023 Medical Expenditure Panel Survey, Prescribed Medicines File (HC-248A) — official documentation, codebook, and Methodology Report #37 on data collection. 192,275 total records (matches AHRQ's published count exactly); 190,730 have a positive person-level weight (PERWT23F). All statistics on this page are unweighted counts of the 187,060 fills with an imputed drug name (5,215 fills with unimputed/missing RXDRGNAM excluded from the drug list). Days-supplied is excluded from day-based metrics for fills with missing (-8/-7) or non-numeric (999 = "taken as needed") RXDAYSUP — per AHRQ, no consistency edits were applied between quantity and days supplied, and no edits were made for very high values. Since the 2017 data, MEPS stopped asking households to report drug payments directly — all expenditure and payer-source figures on this page come from the Pharmacy Component (pharmacy records), not household recall.